ID: h-412e5c37d3
Hypothesis
Intermittent HBOT (2.0 ATA, 60 min, 3x/week) suppresses NLRP3 inflammasome and shifts microglial polarization toward neuroprotective M2 phenotype
This hypothesis proposes that HBOT reduces ROS-mediated NF-κB activation and NLRP3 inflammasome assembly, promoting anti-inflammatory M2 polarization that enhances amyloid phagocytosis.
EvidencePending (0%)📖 0 cit🗣 1 debates✓ 3 support✗ 2 oppose
✓ All Quality Gates Passed
🧪 Overview
This hypothesis proposes that HBOT reduces ROS-mediated NF-κB activation and NLRP3 inflammasome assembly, promoting anti-inflammatory M2 polarization that enhances amyloid phagocytosis. It benefits from clinical relevance (neuroinflammation is a consistent AD finding) but relies on an oversimplified M1/M2 binary framework that does not capture disease-associated microglia (DAM) complexity.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["Target Gene: NLRP3"]
B["Molecular Mechanism<br/>Pathway Activation"]
C["Cellular Phenotype<br/>Neuronal / Glial Response"]
D["Network Effect<br/>Circuit-Level Consequence"]
E["Disease Relevance<br/>Neurodegeneration Link"]
A --> B --> C --> D --> E
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style E fill:#1b5e20,stroke:#81c784,color:#81c784⚖️ Evidence
⚖️ Evidence Matrix3 supports2 contradicts
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — NLRP3
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for NLRP3 from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for NLRP3.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
💰 Estimated Development
Cost
$0
Timeline
—
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▼ 0.6%
Volatility
Low
0.0030
Events (7d)
3
Price History
▼8.4%💾 Resource Usage
LLM Tokens
11,804
$0.0354
Total Cost
$0.0354
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF APP/PS1ΔE9 transgenic mice receive intermittent HBOT (2.0 ATA, 100% O2, 60 min/session, 3 sessions/week for 8 weeks) THEN hippocampal NLRP3 inflammasome activity (measured by caspase-1 FLICA assay | NLRP3 inflammasome activity will be suppressed by ≥30% in HBOT-treated mice relative to sham controls, with corresponding reduction in downstream inflammatory c | — no observation — | pending | 0.65 |
| IF 5xFAD mice receive intermittent HBOT (2.0 ATA, 100% O2, 60 min/session, 3 sessions/week for 8 weeks) THEN the ratio of M2 (CD206+/Arg1+) to M1 (iNOS+/CD16/32+) microglia in cortical and hippocampal | M2/M1 microglial polarization ratio will increase by ≥25% in HBOT-treated mice, indicating a shift toward neuroprotective phenotype with enhanced amyloid phagoc | — no observation — | pending | 0.60 |
🔮 Falsifiable Predictions (2)
pendingconf 65%
IF APP/PS1ΔE9 transgenic mice receive intermittent HBOT (2.0 ATA, 100% O2, 60 min/session, 3 sessions/week for 8 weeks) THEN hippocampal NLRP3 inflammasome activity (measured by caspase-1 FLICA assay and IL-1β protein levels via ELISA) will decrease by ≥30% compared to sham-treated mice within 2 wee
Predicted outcome: NLRP3 inflammasome activity will be suppressed by ≥30% in HBOT-treated mice relative to sham controls, with corresponding reduction in downstream infl
Falsification: NLRP3 inflammasome activity in HBOT-treated mice shows no significant difference (p > 0.05) or increases relative to sham-treated controls.
pendingconf 60%
IF 5xFAD mice receive intermittent HBOT (2.0 ATA, 100% O2, 60 min/session, 3 sessions/week for 8 weeks) THEN the ratio of M2 (CD206+/Arg1+) to M1 (iNOS+/CD16/32+) microglia in cortical and hippocampal regions will increase by ≥25% as assessed by flow cytometry and co-localization immunohistochemistr
Predicted outcome: M2/M1 microglial polarization ratio will increase by ≥25% in HBOT-treated mice, indicating a shift toward neuroprotective phenotype with enhanced amyl
Falsification: M2/M1 microglial ratio in HBOT-treated mice shows no significant increase (p > 0.05) or decreases relative to sham controls, or DAM signatures remain unchanged.
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesizer
| source | v1_phase_c_backfill |
| origin_type | debate_synthesizer |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.